PIK3CA and cervical carcinoma: Using C33A cells as a model for PI3K/AKT mutant cervical cancer, we found that AKT inhibitors effectively block mTORC1/2 signaling, resulting in decreased glucose uptake, glycolysis and cell viability in vitro.